Rezolute posts investor presentation on ersodetug, cites $108 million cash, runway to Q1 2028
Rezolute, Inc. released an investor presentation on its website on October 29, 2026, and furnished it as Exhibit 99.1 to this Form 8-K. The presentation covers its lead candidate ersodetug for congenital and tumor hyperinsulinism, and restates the sunRIZE Phase 3 results, which missed the primary endpoint, alongside an upLIFT tumor HI interim update and an estimated market opportunity above $5 billion.
Key points
- Company reports $108 million in cash with runway through Q1 2028.
- sunRIZE Phase 3 primary endpoint (SMBG weekly hypoglycemia events) was not met; CGM reductions were reported at both doses, with the week 24 result not statistically significant (p=0.30 at 10 mg/kg).
- upLIFT interim: 7 of the initial 8 participants met the primary endpoint; topline results are expected mid-December 2026.
- Presentation cites about 2,000 addressable congenital HI patients and about 6,000 combined U.S. patients, with a combined opportunity exceeding $5 billion.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.